Esophagus, Stomach & Upper GI · Article 102

Which H. pylori Salvage Regimen Should Be Used After Clarithromycin or Bismuth Therapy?

H. pylori salvage therapy requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

H. pylori salvage therapy clinical reference — Related free clinical resource: Endoscopy and Diagnostic Imaging.

H. pylori salvage therapy: practical clinical approach

This page focuses on H. pylori salvage therapy with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for H. pylori salvage therapy

Clinical takeaway: For H. pylori salvage therapy, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Salvage therapy should be chosen from the patient’s prior regimen and known or likely resistance pattern. After failure of clarithromycin-containing therapy, optimized 14-day bismuth quadruple therapy is usually the preferred empiric salvage regimen if it has not already been used. After failure of optimized bismuth quadruple therapy, rifabutin triple therapy or vonoprazan-amoxicillin dual therapy are important options. Clarithromycin and levofloxacin should not be reused empirically after prior exposure; use them only when susceptibility is documented.

After clarithromycin-containing therapy fails

Do not repeat clarithromycin empirically. The probability of clarithromycin resistance is high after exposure, and repeating the same antibiotic architecture produces poor eradication rates. If the patient has not received optimized bismuth quadruple therapy, a 14-day course is generally the most useful next regimen.

After optimized bismuth quadruple therapy fails

First determine whether the regimen was truly optimized: adequate tetracycline and metronidazole dosing, bismuth taken as prescribed, twice-daily potent acid suppression and 14 days of therapy. If it was, a different antibiotic backbone is preferable. Rifabutin-amoxicillin-PPI therapy is attractive because rifabutin resistance is uncommon. Vonoprazan-amoxicillin dual therapy provides potent acid suppression with a simpler antibiotic regimen where available.

Where levofloxacin still fits

Levofloxacin-containing salvage can be effective when the organism is susceptible, but empiric use is increasingly unreliable in regions with high fluoroquinolone resistance. A history of fluoroquinolone exposure for urinary, respiratory or other infections should make clinicians particularly cautious.

Make the regimen executable

Eradication success is not determined by drug selection alone. Simplify schedules when possible, explain expected adverse effects, provide written instructions, address penicillin allergy carefully, and consider whether a reported allergy can be formally evaluated. Amoxicillin remains one of the most useful low-resistance drugs in H. pylori therapy.

Practical clinical algorithm

Identify the exact failed regimen and all prior macrolide/fluoroquinolone exposure.
After failed clarithromycin therapy, use optimized 14-day bismuth quadruple therapy if not previously used.
After failed optimized bismuth quadruple therapy, consider rifabutin triple or vonoprazan-amoxicillin dual therapy.
Use clarithromycin or levofloxacin only when susceptibility is known.
Address adherence, penicillin allergy and drug interactions before prescribing.
Confirm eradication after every salvage course.

Common mistakes to avoid

Treating all prior ‘quadruple therapy’ as though it was optimized.
Reusing clarithromycin because the patient tolerated it well.
Choosing levofloxacin without considering prior community exposure.
Failing to distinguish true penicillin allergy from a historical label.
Not providing a written dosing schedule.

Trainee takeaway

The failed regimen determines the next regimen. Switch antibiotic classes, preserve amoxicillin when possible, exploit optimized bismuth, rifabutin or potent acid-blocker strategies, and verify eradication.

Frequently asked questions

Can I use clarithromycin again if several years have passed?

Not empirically after a prior clarithromycin-containing H. pylori regimen. Susceptibility evidence should guide reuse.

What if tetracycline is unavailable?

Local guideline-supported alternatives may be needed, but doxycycline should not automatically be considered equivalent to tetracycline in optimized bismuth quadruple therapy.

Is rifabutin only a third-line drug?

It is commonly used as salvage, but current guidance recognizes it as an important option when standard regimens are unsuitable or have failed.

References

1. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

3. Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119:1730-1753.

4. Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on Refractory Helicobacter pylori Infection. Gastroenterology. 2021;160:1831-1841.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions